


EARLY TREATMENT IS ESSENTIAL

Regular monitoring from your home allows you and your heart failure medical team to get ahead of heart failure before it progresses.



A study found that with each subsequent heart failure-related admission, the patient leaves the hospital with a further decrease in cardiac function and heart failure prognosis worsens dramatically.¹


In a clinical study of heart failure patients,* the CardioMEMS HF System led to a:

SIGNIFICANT IMPROVEMENT IN QUALITY OF LIFE²

INCREASE IN 6-MINUTE WALK DISTANCE³

REDUCTION IN HEART FAILURE HOSPITALIZATIONS²

STAY AHEAD OF HEART FAILURE AT HOME



How the CardioMEMS™ HF System works

Sensor is inserted using a common procedure.

You simply take a 2-3 minute daily measurement of the sensor from the comfort of your home.

Your health-care provider reviews your information and contacts you when necessary.

FOR MORE INFORMATION VISIT:

StayAheadofHF.com

*In the CHAMPION clinical trial (CardioMEMS Heart Sensor Allows Monitoring of Pressures to Improve Outcomes in NYHA Class III Heart Failure Patients), patients with moderate (NYHA Class III) heart failure for at least three months, irrespective of left ventricular ejection fraction, and a heart failure hospitalization within the past 12 months were included in the study.

1. Bui, A. L., Horwich, T. B., Fonarow, G. C. (2011). Epidemiology and risk profile of heart failure. *Nature Reviews Cardiology*, 8(1), 30-41.
2. Abraham, W. T., Stevenson, L. W., Bourge, R. C., Lindenfeld, J. A., Bauman, J. G., & Adamson, P. B., for the CHAMPION Trial Study Group. (2016). Sustained efficacy of pulmonary artery

pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *The Lancet*, 387(10017), 453-461.

3. Alam, A., Jermyn, R., Joseph, M., Patel, S., Jorde, U., & Saeed, O. (2016, April). *Improved quality of life scores and exercise capacity with remote pulmonary pressure monitoring in patients with chronic heart failure*. Presentation 903-06. American College of Cardiology 2016 Scientific Sessions, Chicago.

Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA
Tel: 1 651 756 2000
SJM.com
St. Jude Medical is now Abbott.

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

Contraindications: The CardioMEMS HF System

is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to the following: Infection, Arrhythmias, Bleeding, Hematoma, Thrombus, Myocardial infarction, Transient ischemic attack, Stroke, Death and Device embolization.

™ Indicates a trademark of the Abbott group of companies.
© 2018 Abbott. All Rights Reserved.

27881-SJM-MEM-0518-0418
Item approved for U.S. use only.

